Skip to main content
Top
Published in: Digestive Diseases and Sciences 9/2008

01-09-2008 | Original Paper

A Meta-Analysis on the Efficacy of Probiotics for Maintenance of Remission and Prevention of Clinical and Endoscopic Relapse in Crohn’s Disease

Authors: Roja Rahimi, Shekoufeh Nikfar, Fatemeh Rahimi, Behzad Elahi, Saeed Derakhshani, Mohammad Vafaie, Mohammad Abdollahi

Published in: Digestive Diseases and Sciences | Issue 9/2008

Login to get access

Abstract

Objective To evaluate whether probiotics maintain remission in patients with Crohn’s disease (CD). Design A meta-analysis of controlled clinical trials. Methods PUBMED and Cochrane Central Register of Controlled Trials were searched for clinical trial studies investigated the efficacy of probiotics for the maintenance of remission in Crohn’s disease. Clinical relapse and endoscopic relapse were the key outcomes of interest. Data were searched within the time period of 1966 through may 2007. Result Eight randomized placebo-controlled clinical trials met our criteria and were included in the analysis. Seven determined clinical relapse and three evaluated endoscopic relapse among patients with CD received probiotics for maintenance of remission. Pooling of seven trials for the outcome of clinical relapse yielded an odds ratio of 0.92 (95% confidence interval of 0.52–1.62, P = 0.8853), a nonsignificant odds ratio. The odds ratio for three studies for the outcome of endoscopic relapse was 0.97 (95% confidence interval of 0.54–1.78, P = 0.93), a nonsignificant odds ratio. Conclusion This meta-analysis fails to demonstrate the efficacy of probiotics in maintaining remission and preventing clinical and endoscopic recurrence in CD. It is suggested to use probiotic preparations containing a mixture of lactobacillus with E. coli or Saccharomyces.
Literature
1.
go back to reference Fow J, Grossman S (2007) A comprehensive guide to patient-focused management strategies for Crohn disease. Gastroenterol Nurs 30:93–98PubMedCrossRef Fow J, Grossman S (2007) A comprehensive guide to patient-focused management strategies for Crohn disease. Gastroenterol Nurs 30:93–98PubMedCrossRef
2.
go back to reference Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, Pallone F (2003) Review article: maintenance treatment of Crohn’s disease. Aliment Pharmacol Ther 17:S31–S37CrossRef Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, Pallone F (2003) Review article: maintenance treatment of Crohn’s disease. Aliment Pharmacol Ther 17:S31–S37CrossRef
3.
go back to reference Lemann M (2006) Review article: can post-operative recurrence in Crohn’s disease be prevented? Aliment Pharmacol Ther 24:S22–S28CrossRef Lemann M (2006) Review article: can post-operative recurrence in Crohn’s disease be prevented? Aliment Pharmacol Ther 24:S22–S28CrossRef
4.
go back to reference Akobeng AK, Gardener E (2005) Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s Disease. Cochrane Database Syst Rev 25:CD003715 Akobeng AK, Gardener E (2005) Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s Disease. Cochrane Database Syst Rev 25:CD003715
5.
go back to reference Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO (2003) Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 4:CD000301PubMed Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO (2003) Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 4:CD000301PubMed
6.
go back to reference Jones JL, Foxx-Orenstein AE (2007) The role of probiotics in inflammatory bowel disease. Dig Dis Sci 52:607–611PubMedCrossRef Jones JL, Foxx-Orenstein AE (2007) The role of probiotics in inflammatory bowel disease. Dig Dis Sci 52:607–611PubMedCrossRef
7.
8.
go back to reference Sartor RB (2003) Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. Curr Opin Gastroenterol 19:358–365PubMedCrossRef Sartor RB (2003) Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. Curr Opin Gastroenterol 19:358–365PubMedCrossRef
9.
go back to reference Gionchetti P, Rizzello F, Campieri M (2002) Probiotics in gastroenterology. Curr Opin Gastroenterol 18:235–239PubMedCrossRef Gionchetti P, Rizzello F, Campieri M (2002) Probiotics in gastroenterology. Curr Opin Gastroenterol 18:235–239PubMedCrossRef
10.
go back to reference Guslandi M, Mezzi G, Sorghi M, Testoni PA (2000) Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 45:1462–1464PubMedCrossRef Guslandi M, Mezzi G, Sorghi M, Testoni PA (2000) Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 45:1462–1464PubMedCrossRef
11.
go back to reference Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut 51:405–409PubMedCrossRef Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut 51:405–409PubMedCrossRef
12.
go back to reference Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F (2006) Probiotics for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 18:CD004826 Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F (2006) Probiotics for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 18:CD004826
13.
go back to reference Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, Murray KF, Oliva-Hemker M, Rosh JR, Tolia V, Zholudev A, Vanderhoof JA, Hibberd PL (2005) A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis 11:833–839PubMedCrossRef Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, Murray KF, Oliva-Hemker M, Rosh JR, Tolia V, Zholudev A, Vanderhoof JA, Hibberd PL (2005) A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis 11:833–839PubMedCrossRef
14.
go back to reference Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC (2004) Lactobacillus GG in inducing and maintaining remission of Crohn’s disease BMC Gastroenterol 4:5PubMedCrossRef Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC (2004) Lactobacillus GG in inducing and maintaining remission of Crohn’s disease BMC Gastroenterol 4:5PubMedCrossRef
15.
go back to reference Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, Cadiot G, Soule JC, Bourreille A, Metman E, Lerebours E, Carbonnel F, Dupas JL, Veyrac M, Coffin B, Moreau J, Abitbol V, Blum-Sperisen S, Mary JY (2006) Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55:842–847PubMedCrossRef Marteau P, Lemann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, Cadiot G, Soule JC, Bourreille A, Metman E, Lerebours E, Carbonnel F, Dupas JL, Veyrac M, Coffin B, Moreau J, Abitbol V, Blum-Sperisen S, Mary JY (2006) Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55:842–847PubMedCrossRef
16.
go back to reference Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F, DeVos M, Enslen M, Paintin M, Franchimont D (2007) Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after lleo-caecal resection. Inflamm Bowel Dis 13:135–142PubMedCrossRef Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F, DeVos M, Enslen M, Paintin M, Franchimont D (2007) Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after lleo-caecal resection. Inflamm Bowel Dis 13:135–142PubMedCrossRef
17.
go back to reference Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A (2006) Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 23:1567–1574PubMedCrossRef Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A (2006) Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 23:1567–1574PubMedCrossRef
18.
go back to reference Malchow HA (1997) Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol 25:653–658PubMedCrossRef Malchow HA (1997) Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol 25:653–658PubMedCrossRef
19.
go back to reference Rahimi R, Nikfar S, Rezaie A, Abdollahi M (2006) A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s disease. Clin Ther 28:1983–1988PubMedCrossRef Rahimi R, Nikfar S, Rezaie A, Abdollahi M (2006) A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s disease. Clin Ther 28:1983–1988PubMedCrossRef
20.
go back to reference MacDonald JK, McDonald JW (2007) Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 1:CD006097PubMed MacDonald JK, McDonald JW (2007) Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 1:CD006097PubMed
21.
go back to reference Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG (2002) The effectiveness of budesonide therapy for Crohn’s disease. Aliment Pharmacol Ther 16:1509–1517PubMedCrossRef Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG (2002) The effectiveness of budesonide therapy for Crohn’s disease. Aliment Pharmacol Ther 16:1509–1517PubMedCrossRef
22.
go back to reference Campieri M, Rizzello F, Venturi A, Poggioli G, Ugolini F, Helwig U, Amadini C, Romboli E, Gionchetti P (2000) Combination of antibiotic and probiotic treatment in efficacious in prophylaxis of post-operative recurrence of crohn’s disease: a randomized controlled study versus mezalamine. Gastroenterology 118:A781CrossRef Campieri M, Rizzello F, Venturi A, Poggioli G, Ugolini F, Helwig U, Amadini C, Romboli E, Gionchetti P (2000) Combination of antibiotic and probiotic treatment in efficacious in prophylaxis of post-operative recurrence of crohn’s disease: a randomized controlled study versus mezalamine. Gastroenterology 118:A781CrossRef
23.
go back to reference Malin M, Suomalainen H, Saxelin M, Isolauri E (1996) Promotion of IgA immune response in patients with Crohn’s disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 40:137–145PubMedCrossRef Malin M, Suomalainen H, Saxelin M, Isolauri E (1996) Promotion of IgA immune response in patients with Crohn’s disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 40:137–145PubMedCrossRef
Metadata
Title
A Meta-Analysis on the Efficacy of Probiotics for Maintenance of Remission and Prevention of Clinical and Endoscopic Relapse in Crohn’s Disease
Authors
Roja Rahimi
Shekoufeh Nikfar
Fatemeh Rahimi
Behzad Elahi
Saeed Derakhshani
Mohammad Vafaie
Mohammad Abdollahi
Publication date
01-09-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-0171-0

Other articles of this Issue 9/2008

Digestive Diseases and Sciences 9/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine